UPF spinoff Integra Therapeutics obtains 4.5 million euros to develop its genetic editing technology
Investment funds Takeda Ventures, Advent France Biotechnology and Invivo Capital have invested in the company, which is working on a technology platform to improve the effectiveness and safety of advanced therapies.
|